Cargando…
Bone-targeted agents in multiple myeloma
Osteolytic bone disease, characterized by bone pain, increased risk of pathologic fractures, tumor-induced hypercalcemia known as skeletal-related events (SREs), is a frequent complication of patients with multiple myeloma (MM) and persists even in the absence of active disease, resulting in a major...
Autor principal: | Nishida, Hiroko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907643/ https://www.ncbi.nlm.nih.gov/pubmed/29721251 http://dx.doi.org/10.4081/hr.2018.7401 |
Ejemplares similares
-
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
por: Nishida, Hiroko, et al.
Publicado: (2019) -
Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
por: Nishida, Hiroko
Publicado: (2021) -
Innovative Agents in Multiple Myeloma
por: Faiman, Beth, et al.
Publicado: (2014) -
The role of bone‐modifying agents in myeloma bone disease
por: Lu, Huifang, et al.
Publicado: (2021) -
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
por: Larsen, Jeremy T., et al.
Publicado: (2015)